UPDATE 1-EU agency recommends new drugs from Roche, Biogen and PTC

May 23, 2014 12:45 PM

3 0

LONDON May 23 (Reuters) - European regulators said on Friday they had recommended approval of Roche's drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic leukaemia, boosting the Swiss group's line-up of new cancer treatments.

The new medicine is an improved follow-on medicine to Roche's $7 billion-a-year Rituxan, or MabThera, and Roche is hoping to switch as many patients as possible to the newer product before Rituxan faces competition from cheaper copies.

Read more

To category page